Premium
Designing neuroprotection trials in Parkinson's disease
Author(s) -
Kieburtz Karl
Publication year - 2003
Publication title -
annals of neurology
Language(s) - English
Resource type - Journals
SCImago Journal Rank - 4.764
H-Index - 296
eISSN - 1531-8249
pISSN - 0364-5134
DOI - 10.1002/ana.10484
Subject(s) - neuroprotection , parkinson's disease , medicine , disease , neuroscience , intensive care medicine , physical medicine and rehabilitation , psychology , pharmacology
A major goal of the neuroscience community is to develop neuroprotective treatment strategies that will slow or forestall the progression of Parkinson's disease, one of the most common adult‐onset neurodegenerative disorders, affecting approximately 1 million people in North America. Although prior research to identify neuroprotective interventions has not been conclusive, recent advances in the understanding of the pathogenesis of Parkinson's disease, including the development of relevant animal models, provide the opportunity for rational clinical trials to assess neuroprotective treatments.Ann Neurol 2003;53 (suppl 3):S100–S109